IDH2 mutations were first detected in gliomas by Yan et al. [3]; similar to IDH1 mutations, IDH2 mutation were associated with a better prognosis, although these mutations occurred at considerable lower frequency. This evidence concerns the gene IDH1 and central nervous system cancer.